Japanese approval completes the set for Maviret in major markets

AbbVie’s Maviret (glecaprevir/pibrentasvir) has been approved in Japan as a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes.

It is the first and only treatment for genotype one (GT1) and two HCV patients without cirrhosis and who are new to direct-acting antivirals in Japan, including those with chronic kidney disease. These patients represent most of those with HCV in the Asian country, which has one of the industrialized world’s highest HCV infection rates, and 97% of the 2 million people affected have GT1 and GT2 chronic HCV.

Maviret has also received recent approval in the USA and Europe.